Eiger Financial Statements From 2010 to 2024
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Check Eiger Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eiger Biopharmaceutica's main balance sheet or income statement drivers, such as , as well as many indicators such as . Eiger financial statements analysis is a perfect complement when working with Eiger Biopharmaceutica Valuation or Volatility modules.
Eiger |
Eiger Biopharmaceuticals Company Current Valuation Analysis
Eiger Biopharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eiger Biopharmaceutica Current Valuation | 3.88 M |
Most of Eiger Biopharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eiger Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Eiger Biopharmaceuticals has a Current Valuation of 3.88 M. This is 99.97% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Eiger Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eiger Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Eiger Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eiger Biopharmaceutica competition to find correlations between indicators driving Eiger Biopharmaceutica's intrinsic value. More Info.Eiger Biopharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Eiger Biopharmaceutica by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Eiger Biopharmaceutica Financial Statements
Eiger Biopharmaceutica shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Eiger Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. The changes in Eiger Biopharmaceutica's assets and liabilities, for example, are also reflected in the revenues and expenses on on Eiger Biopharmaceutica's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Eiger Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.
Pair Trading with Eiger Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with Eiger Stock
| 0.83 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.65 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.61 | BKRKF | PT Bank Rakyat | PairCorr |
Moving against Eiger Stock
| 0.79 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.75 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.66 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.65 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.65 | WMT | Walmart Aggressive Push | PairCorr |
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |